NASDAQ · ADUS
Healthcare · Medical - Care Facilities
$125.54
Up+$1.20 (+0.97%)
Updated Oct 31, 2026, 7:00 PM
SID Score
5.9/10
Composite research score
Smart Money
—
Institutional and insider signal
Price performance · ADUS
1M range · 21 trading sessions · Daily adjusted prices
Prices through Oct 30, 2026
ADUS closed at $125.54 after 21 trading sessions, up 12.82% for the selected period.
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Oct 30, 2026 | $125.65 | $126.62 | $124.45 | $125.54 | 300.31K |
| Oct 29, 2026 | $124.61 | $125.50 | $122.565 | $124.34 | 331.55K |
| Oct 28, 2026 | $121.15 | $123.07 | $120.03 | $122.18 | 312.15K |
| Oct 27, 2026 | $121.37 | $122.13 | $120.51 | $121.24 | 216.64K |
| Oct 26, 2026 | $122.34 | $123.4675 | $120.66 | $121.17 | 202.75K |
| Oct 23, 2026 | $122.35 | $123.01 | $120.75 | $121.81 | 224.26K |
| Oct 22, 2026 | $118.78 | $123.185 | $118.38 | $122.67 | 147.48K |
| Oct 21, 2026 | $118.02 | $118.81 | $116.255 | $117.95 | 163.6K |
| Oct 20, 2026 | $116.09 | $118.18 | $116.09 | $118.03 | 138.92K |
| Oct 19, 2026 | $115.98 | $116.85 | $114.71 | $115.16 | 130.41K |
| Oct 16, 2026 | $116.91 | $117.48 | $115.735 | $115.98 | 136.89K |
| Oct 15, 2026 | $117.63 | $118.38 | $116.20 | $116.49 | 172.42K |
| Oct 14, 2026 | $114.34 | $117.10 | $114.17 | $116.62 | 249.67K |
| Oct 13, 2026 | $116.45 | $116.50 | $114.41 | $114.53 | 145.6K |
| Oct 12, 2026 | $115.31 | $117.32 | $114.5325 | $115.475 | 197.86K |
| Oct 9, 2026 | $113.84 | $115.10 | $113.84 | $114.33 | 172.78K |
| Oct 8, 2026 | $113.43 | $115.85 | $112.72 | $114.26 | 146.58K |
| Oct 7, 2026 | $113.16 | $117.313 | $112.905 | $113.27 | 229.45K |
| Oct 6, 2026 | $114.00 | $114.66 | $112.24 | $113.16 | 125.55K |
| Oct 5, 2026 | $111.49 | $113.80 | $110.235 | $112.98 | 218.29K |
| Oct 2, 2026 | $112.37 | $113.075 | $111.135 | $111.27 | 207.75K |
The latest Smart Investors Daily articles mentioning ADUS.
Company
Market Activity
Research & News
ADUS research
Company profile and research snapshot.
Addus HomeCare Corp is engaged in the provision of in-home care services. The Company has three reportable segments: Personal Care, Hospice, and Home Health. The Personal Care segment provides non-medical assistance with activities of daily living, mainly to the elderly, chronically ill, and disabled individuals. The Hospice segment provides physical, emotional, and spiritual care for terminally ill patients and their families. The Home Health segment provides medical services to individuals requiring care during illness or recovery. It generates the majority of its revenue from the Personal Care segment.
Visit company websiteConsensus and target data currently published for this company.
| Date | Firm | Rating | Target |
|---|---|---|---|
| Sep 14, 2026 | B of A Securities | Neutral | — |
| Aug 5, 2026 | RBC Capital | Outperform | — |
| Jul 9, 2026 | Barclays | Underweight | — |
| May 18, 2026 | Citizens | Market Outperform | — |
| May 15, 2026 | Barclays | Underweight | — |
No generated briefing is available yet.
Yahoo · Oct 22, 2026
Quest Diagnostics (DGX) delivered earnings and revenue surprises of +5.26% and +1.72%, respectively, for the quarter ended September 2026. Do the numbers hold clues to what lies ahead for the stock?
Yahoo · Oct 19, 2026
The June closing of the Eucalyptus acquisition transformed Hims & Hers Health (HIMS) into what the company now calls a global consumer health platform. Bears may be overlooking this shift. Investors probably still view the firm as a U.S. telehealth company. The company is losing money, and the stock lost 55.3% in twelve months while the S&P 500 gained 16.2%. So, how big is Hims & Hers outside the U.S.
Yahoo · Oct 13, 2026
FRISCO, Texas, October 13, 2026--Addus HomeCare Corporation (Nasdaq: ADUS), a provider of home care services, announced today that it will release earnings for the third quarter ended September 30, 2026, on Tuesday, November 3, 2026, after the market close.
Yahoo · Oct 12, 2026
Investors holding Hims & Hers Health (HIMS) face a stark contradiction. The stock has lost 52% in twelve months, while the S&P 500 returned 17.0%. Following that decline, shares now trade at 2.8 times sales, against 3.1 for the index. Yet the company grew sales nearly 40% in fiscal Q2 2026. So where is that growth coming from.
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
The latest Smart Investors Daily articles mentioning ADUS.
